DNA methylation of<i> ANKRD23</i> as a novel biomarker for early diagnosis of ovarian cancer
AFRICAN JOURNAL OF REPRODUCTIVE HEALTH, cilt.30, sa.15, ss.16-25, 2026 (SSCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 15
- Basım Tarihi: 2026
- Doi Numarası: 10.29063/ajrh2026/v30i15.2
- Dergi Adı: AFRICAN JOURNAL OF REPRODUCTIVE HEALTH
- Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, CAB Abstracts, CINAHL, Index Islamicus, MEDLINE, Middle East & Africa Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.16-25
- İstanbul Üniversitesi Adresli: Evet
Özet
Ovarian cancer (OC) is a leading cause of gynecologic cancer-related mortality and is frequently diagnosed at advanced stages due to the absence of effective early detection tools. Epigenetic alterations, particularly DNA methylation, play a critical role in tumorigenesis and represent promising non-invasive biomarkers. This study investigated the methylation status of the ANKRD23 gene in OC and evaluated its diagnostic potential using peripheral blood samples. A total of 385 serous OC patients, 50 individuals with benign ovarian conditions, and 99 healthy controls were included. DNA methylation was assessed using methylation-sensitive restriction enzymes followed by real-time PCR. ANKRD23 methylation was significantly associated with clinical stage (p = 0.029), histological grade (p = 0.009), and ethnicity (p = 0.024). Moreover, methylation levels differed significantly among OC patients, benign cases, and healthy controls (p = 0.026). These findings support blood-basedANKRD23 methylation as a promising biomarker for non-invasive ovarian cancer diagnosis and risk stratification. (Afr JReprod Health 2026; 30 [15] 16-25).